Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Tablets: SOP for Validating Computerized Systems in QA – V 2.0

Posted on By

Tablets: SOP for Validating Computerized Systems in QA – V 2.0

Standard Operating Procedure for Validating Computerized Systems in QA

Department Tablet
SOP No. SOP/TAB/227/2025
Supersedes SOP/TAB/227/2022
Page No. Page 1 of 5
Issue Date 01/03/2026
Effective Date 06/03/2026
Review Date 01/03/2027

1. Purpose

The purpose of this SOP is to establish the procedure for validating computerized systems used in Quality Assurance (QA). The goal is to ensure that all computerized systems used for data collection, analysis, and reporting comply with regulatory requirements and industry standards, such as 21 CFR Part 11.

2. Scope

This SOP applies to all computerized systems used in QA, including Laboratory Information Management Systems (LIMS), Manufacturing Execution Systems (MES), data loggers, and other software applications used for tracking, testing, and reporting quality data. The SOP covers the entire validation process from planning to execution and ongoing monitoring.

3. Responsibilities

  • QA Manager: Responsible for overseeing the entire validation process of computerized systems and ensuring that the systems meet regulatory compliance and internal quality standards.
  • IT Team: Responsible for providing technical support, ensuring system security, and facilitating the installation, configuration, and maintenance of computerized systems.
  • System Owner: Responsible for ensuring the system’s functionality aligns with quality objectives and requirements and overseeing the
user acceptance testing.
  • Regulatory Affairs Team: Ensures that the computerized systems meet all applicable regulatory requirements, including compliance with 21 CFR Part 11 and other relevant guidelines.
  • 4. Accountability

    The QA Manager is accountable for ensuring that all computerized systems are validated and operate within the specified requirements. The IT and System Owner teams are responsible for executing the technical and functional aspects of validation, while the Regulatory Affairs team ensures compliance with regulatory requirements.

    5. Procedure

    5.1 Validation Planning

    1. Identify the computerized system that requires validation, including its intended use and critical functions (Annexure-1).
    2. Develop a Validation Plan that includes the scope, resources, responsibilities, testing requirements, and timelines for the validation process (Annexure-2).
    3. Ensure that the Validation Plan aligns with applicable regulatory requirements, such as 21 CFR Part 11 (Annexure-3).
    4. Obtain approval from the QA Manager and relevant stakeholders before proceeding with the validation process.

    5.2 System Installation Qualification (IQ)

    1. Verify that the system has been properly installed according to the manufacturer’s specifications and the validation plan (Annexure-4).
    2. Ensure that hardware, software, and network configurations are correctly set up and meet the requirements specified in the Validation Plan.
    3. Document the installation process, including verification of the system’s components and configuration (Annexure-5).
    4. Ensure that all relevant documentation (e.g., system manuals, configuration files, licenses) is available for review and storage.

    5.3 Operational Qualification (OQ)

    1. Test the system’s functionality to ensure that it operates according to its specifications under normal operating conditions (Annexure-6).
    2. Verify that all critical features, such as data input, processing, output, and reporting, function as required.
    3. Document the test results, including any deviations or non-conformities, and ensure corrective actions are taken as needed (Annexure-7).
    4. Ensure that the system meets all internal and external quality and compliance requirements, such as data integrity, user access control, and audit trails.

    5.4 Performance Qualification (PQ)

    1. Verify that the system performs consistently and reliably over time under actual operational conditions (Annexure-8).
    2. Test the system with real data to ensure that it produces accurate and reliable results that meet quality standards.
    3. Ensure that the system meets all acceptance criteria outlined in the Validation Plan and that any deviations are addressed (Annexure-9).
    4. Document the results of the performance qualification tests and retain them for future audits and inspections.

    5.5 Documentation and Record Keeping

    1. Ensure that all validation activities, including IQ, OQ, and PQ, are thoroughly documented and stored securely (Annexure-10).
    2. Maintain all validation records for a minimum of 5 years or as required by regulatory authorities.
    3. Ensure that all records are accessible for audits and inspections by regulatory agencies (Annexure-11).

    5.6 Change Control and Revalidation

    1. Any changes made to the computerized system (e.g., upgrades, patches, configuration changes) must be evaluated for potential impact on system validation (Annexure-12).
    2. If significant changes are made, the system must undergo revalidation to ensure that it continues to meet its specifications and compliance requirements.
    3. Document all changes and revalidation activities in the Change Control Log (Annexure-13).

    5.7 Ongoing System Monitoring

    1. Monitor the performance of the computerized system during its lifecycle to ensure that it continues to meet functional and regulatory requirements (Annexure-14).
    2. Conduct regular system audits and review user access logs to ensure data integrity, security, and compliance with applicable regulations (Annexure-15).
    3. Address any issues identified during ongoing monitoring and update the system as necessary to maintain compliance.

    6. Abbreviations

    • SOP: Standard Operating Procedure
    • QA: Quality Assurance
    • OQ: Operational Qualification
    • PQ: Performance Qualification
    • IQ: Installation Qualification
    • GMP: Good Manufacturing Practice
    • 21 CFR Part 11: FDA Regulations for Electronic Records and Signatures

    7. Documents

    1. Validation Plan (Annexure-1)
    2. System Installation Checklist (Annexure-2)
    3. System Validation Report (Annexure-3)
    4. Installation Qualification Test Results (Annexure-4)
    5. Operational Qualification Test Plan (Annexure-5)
    6. Operational Qualification Test Results (Annexure-6)
    7. Performance Qualification Test Plan (Annexure-7)
    8. Performance Qualification Test Results (Annexure-8)
    9. System Documentation Log (Annexure-9)
    10. Change Control Log (Annexure-10)
    11. Revalidation Documentation (Annexure-11)
    12. System Monitoring Log (Annexure-12)

    8. References

    • 21 CFR Part 11 – Electronic Records and Electronic Signatures (FDA)
    • ISO 9001 – Quality Management Systems
    • ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Validation Plan

    System Intended Use Validation Scope Validation Methodology
    LIMS Laboratory Data Management IQ, OQ, PQ Vendor and internal testing

    Annexure-2: System Installation Checklist

    Component Specification Pass/Fail
    Software Installation Correct version and configuration Pass

    Revision History:

    Revision Date Revision No. Revision Details Reason for Revision Approved By
    01/01/2024 1.0 Initial SOP creation New process QA Head
    01/02/2025 2.0 Updated validation steps to include ongoing monitoring Process improvement QA Head
    See also  Tablets: SOP for Applying Film Coating to Tablets - V 2.0
    Tablet Manufacturing V2.0 Tags:GMP tablet manufacturing SOP, SOP for tablet production, SOP for tablet quality control, SOP tablet inspection process, SOP tablet packing and sealing, Tablet batch record review, Tablet blending SOP, Tablet cleaning and maintenance, Tablet coating procedure, Tablet compression SOP, Tablet disintegration test procedure, Tablet dissolution procedure, Tablet formulation SOP, Tablet friability testing SOP, Tablet labeling and packaging SOP, Tablet manufacturing equipment SOP, Tablet manufacturing SOP, Tablet manufacturing SOPs, Tablet packaging SOP, Tablet production procedure, Tablet quality assurance SOP, Tablet quality control SOP, Tablet sampling and in-process testing SOP, Tablet stability testing SOP, Tablet storage and handling procedure, Tablet uniformity testing procedure, Tablet weight variation SOP

    Post navigation

    Previous Post: API Manufacturing: SOP for Stock Inventory Management and Cycle Counting – V 2.0
    Next Post: BA-BE Studies: SOP for Compliance with ICH E6(R2) GCP Addendum – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version